Pfizer
Pfizer (ファイザー株式会社) is a global research-based pharmaceutical company that develops, manufactures, and sells prescription drugs and vaccines across oncology, vaccines, internal medicine, and inflammation/immunology, serving hospitals, clinics, healthcare providers, and patients worldwide via medical representatives and global supply chain.
- Company typePublic
- Founded1849
- HeadquartersTokyo, Japan
- Headcount1,001–5,000
- GTM typeB2B
- OfferingHardware or Manufacturing
What Pfizer does
Pfizer Japan Inc. (ファイザー株式会社) is the Japanese operating subsidiary of Pfizer Inc., a Delaware-incorporated, NYSE-listed (PFE) global biopharmaceutical company headquartered in New York and founded in 1849. Pfizer Japan, headquartered in Shibuya-ku, Tokyo with a Pfizer Global Supply manufacturing facility in Nagoya, researches, develops, manufactures, and sells innovative prescription pharmaceuticals and vaccines. The company is organized around four end-to-end therapeutic areas: oncology, vaccines, internal medicine, and inflammation and immunology, with oncology further focused on breast, urologic, hematologic, and thoracic cancers.
The portfolio spans multiple drug modalities including small molecule compounds, mRNA vaccines (Comirnaty co-developed with BioNTech), antibody-drug conjugates (ADCs), bispecific antibodies (e.g., elranatamab), and gene therapy. Approved and pipeline products include Ibrance, Lorbrena, Abrysvo, Vepdegestrant/ARV-471, rimegepant/Nurtec, ritlecitinib, abrocitinib, Paxlovid, and vaccines for RSV, GBS, and C. difficile. Pfizer Japan also runs patient support platforms (the "がんと歩む" cancer patient app, ganclass.jp, enkei-datsumou.jp) and operates co-promotion partnerships with Bristol-Myers Squibb (Eliquis), Astellas (Abrysvo), and Tanabe Pharma (Govick).
Pfizer generates revenue primarily through prescription pharmaceutical and vaccine sales distributed via medical representatives (MRs) to hospitals, clinics, and pharmacies in Japan, with global manufacturing and supply through Pfizer Global Supply (PGS). Full-year 2024 consolidated revenue was $63.6 billion (up 6.7% YoY, 12% ex-COVID operational growth). Additional revenue streams include licensing deals (e.g., the $1.25 billion 3SBIO licensing arrangement). Pfizer also maintains licensing arrangements and co-development partnerships, and conducts over 50 clinical trials globally.
Pfizer firmographics
Firmographics- Name
- Pfizer
- Legal name
- ファイザー株式会社
- Website
- https://pfizer.co.jp
- Company type
- Public
- Founded year
- 1849
- Operating status
- Operating
- Headcount range
- 1,001–5,000 employees
- Short description
- Pfizer (ファイザー株式会社) is a global research-based pharmaceutical company that develops, manufactures, and sells prescription drugs and vaccines across oncology, vaccines, internal medicine, and inflammation/immunology, serving hospitals, clinics, healthcare providers, and patients worldwide via medical representatives and global supply chain.
- Ownership category
- akta.pro rank
Pfizer industry classification
Industry- Product category
- Pharmaceutical Drugs and Vaccines
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Prophylactic Human Vaccines (routine, pediatric, adult) (HLAAAEAA)
- akta.pro secondary industries
- Infectious Disease & Pandemic Preparedness Vaccines (emerging pathogens) (HLAAAEAC), Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA) (HLAAAEAD), Clinical Development & Regulatory for Vaccines (trials, pharmacovigilance, lot release) (HLAAAEAK)
Keywords
Where Pfizer is headquartered
LocationHeadquarters
- HQ city
- Tokyo
- HQ country
- Japan
- HQ region
- Asia
Offices2 records
Markets served
Pfizer business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Supply Chain, Marketing or Sales, Operations
Revenue model
- Pharmaceutical product sales: Pfizer generates revenue primarily through the sale of prescription pharmaceuticals and vaccines. Full-year 2024 revenue was $63.6 billion, up 6.7% year-over-year. Operational growth excluding COVID products was 12%, driven by oncology, cardiovascular, and vaccine portfolios.
- Vaccines (Comirnaty): COVID-19 vaccine Comirnaty and related vaccine products for various age groups, approved for Omicron variant JN.1 lineage LP.8.1
- Licensing deals: $1.25 billion licensing deal with Chinese biopharma 3SBIO
Go-to-market motion2 records
Distribution channels3 records
Marketing channels6 records
Pfizer product offering
Product offeringCore offering
Pfizer researches, develops, manufactures, and commercializes prescription pharmaceuticals and vaccines across four therapeutic areas: oncology, vaccines, internal medicine, and inflammation and immunology. Key products include Comirnaty (COVID-19 mRNA vaccine), Abrysvo (RSV vaccine), Ibrance (breast cancer), Lorbrena (lung cancer), Elranatamab (multiple myeloma), and Paxlovid (COVID-19 antiviral). The company serves healthcare providers, hospitals, clinics, and patients globally.
Product overview
Pfizer is a research-based pharmaceutical company with four end-to-end therapeutic areas: oncology, vaccines, internal medicine, and inflammation and immunology. The oncology portfolio focuses on four key areas (breast cancer, urological cancer, hematologic cancer, and thoracic/lung cancer) utilizing diverse drug technologies including small molecules, antibody-drug conjugates (ADCs), and bispecific antibodies. The vaccine portfolio includes Comirnaty (COVID-19 mRNA vaccine with BioNTech), Abrysvo (RSV vaccine), and pipeline candidates for RSV, GBS, and C. difficile. Internal medicine includes cardiovascular treatments, migraine treatments (rimegepant), and obesity treatments. The inflammation and immunology portfolio includes treatments for atopic dermatitis (abrocitinib, crisaborole), ulcerative colitis (tofacitinib, etrasimod), and alopecia areata (ritlecitinib). In 2024, Pfizer reported full-year revenue of $63.6 billion with operational growth excluding COVID products at 12%.
Differentiator
Problem solved
Functional benefit
Brands
- がんと歩む: Cancer patient support app for managing daily life, tracking health, and accessing cancer-related information
- Comirnaty
- ABRYSVO
- パキロビッドパック
- プレベナー20
- タイコバック
Products and services
- Comirnaty (COVID-19 Vaccine) mRNA-based COVID-19 vaccine developed in partnership with BioNTech, approved for multiple age groups including adults, children ages 5-11, and infants 6 months and older.
- Abrysvo (RSV Vaccine) Respiratory syncytial virus (RSV) vaccine approved for adults, including expanded EU approval for adults aged 18-59 against RSV lower respiratory tract disease.
- Paxlovid (Nirmatrelvir/Ritonavir)
Quantifiable outcome
- Full-year 2024 revenue of $63.6 billion, up 6.7% year-over-year
- +1 more outcomes
Companies that use Pfizer
Customer profileNamed customers1 record
Segments4 records
Ideal customer profiles3 records
Pfizer technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Pfizer partnerships and signals
Strategic signalPartnerships
Six partnerships are on record, tiered core and minor.
- BioNTechcorePfizer and BioNTech have obtained manufacturing and sales approval for COVID-19 vaccine Comirnaty for various age groups targeting the Omicron variant JN.1 lineage LP.8.1. The partnership combines BioNTech's mRNA technology with Pfizer's global manufacturing and distribution capabilities.
- ArvinasminorPfizer and Arvinas announced positive topline results from Phase 3 VERITAC-2 clinical trial. Arvinas is developing PF-07850327 (ARV-471) for ER-positive/HER2-negative breast cancer, with Pfizer collaborating on clinical development.
- PAHO, Argentina, and SinergiumminorPAHO, Argentina, Pfizer, and Sinergium are driving local production of 20-valent pneumococcal vaccine for Latin America and the Caribbean. This partnership aims to improve vaccine access and supply in the region.
- Bristol-Myers SquibbcoreCo-promotion partnership for Eliquis (apixaban) in Japan. Both companies share information and coordinate on product promotion, clinical trials, and regulatory matters related to this anticoagulant medication.
- Tanabe PharmaminorProduct: Govick injection for subcutaneous use. Partnership for co-promotion and information sharing in Japan.
- Astellas PharmaminorProduct: Abrysvo. Partnership for co-promotion and information sharing in Japan for the RSV vaccine.
Scale indicators5 records
Recent moves6 records
Expansion highlights6 records
Pfizer competitors and assessment
Company assessmentDirect peers
- GSK: Direct competitor in vaccines (Shingrix, Arexvy vs. Pfizer's Abrysvo) and specialty pharmaceuticals; competes with Pfizer in respiratory, HIV, and oncology adjacencies.
- Novartis: Diversified global pharmaceutical company with overlapping oncology, cardiovascular, and immunology portfolios; comparable revenue scale and prescriber-channel business model.
- Moderna: Pure-play mRNA therapeutics and vaccines company; competes directly with Pfizer/BioNTech in COVID, RSV, and flu vaccines, and pursues similar oncology and rare disease mRNA programs.
- AstraZeneca: Major pharma with strong oncology (Tagrisso, Imfinzi) and biologics platforms; competes with Pfizer in ADC development, vaccines, and cardiovascular/inflammation therapies.
- Merck & Co. (MSD): Global research-based pharmaceutical company with similarly broad oncology and vaccine portfolios (Keytruda, Gardasil); competes head-to-head with Pfizer in oncology, vaccines, and hospital channel sales worldwide.
- Johnson & Johnson (Innovative Medicine): Major diversified pharma with overlapping oncology, immunology, and vaccine franchises; comparable global scale, R&D budget, and prescriber-focused commercial model.
- Bristol-Myers Squibb: Co-promotion partner on Eliquis and direct oncology competitor (Opdivo, Yervoy); comparable focus on oncology, hematology, and cardiovascular franchises with overlapping prescriber base.
- BioNTech: Co-development partner on Comirnaty and independent mRNA competitor; directly comparable in mRNA technology platform, vaccine pipeline, and oncology immunotherapy programs.
- Sanofi: Global vaccines and specialty care leader (Fluzone, Dupixent); competes with Pfizer across vaccines, immunology, and rare disease, with similar global commercial and manufacturing footprint.
Emerging players
- Eli Lilly: Competitor in metabolic disease and oncology; Pfizer's exit from oral GLP-1 obesity (danuglipron) leaves Lilly dominant in the space, making it the leading obesity peer against which Pfizer's internal medicine pipeline is benchmarked.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks5 records
Key highlights7 records
Customer concentration
Pfizer social profiles
Digital presencePfizer financial estimates
Financial estimateRevenue estimate
Valuation estimate
Pfizer leadership team
Management profileNumber of profiles
Profiles1 record
Pfizer subsidiaries and ownership
Company hierarchySubsidiaries3 records
Pfizer funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Pfizer M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Pfizer
What does Pfizer do?
Pfizer researches, develops, manufactures, and commercializes prescription pharmaceuticals and vaccines across four therapeutic areas: oncology, vaccines, internal medicine, and inflammation and immunology. Key products include Comirnaty (COVID-19 mRNA vaccine), Abrysvo (RSV vaccine), Ibrance (breast cancer), Lorbrena (lung cancer), Elranatamab (multiple myeloma), and Paxlovid (COVID-19 antiviral). The company serves healthcare providers, hospitals, clinics, and patients globally.
Is Pfizer a public or private company?
Pfizer is a public company. It is classified as public and is currently operating.
When was Pfizer founded?
Pfizer was founded in 1849. It employs 1,001 to 5,000 people.
Where is Pfizer based?
Pfizer is headquartered in Tokyo, Japan, in the Asia region.
How does Pfizer make money?
Three revenue lines are on record. Pharmaceutical product sales are the primary driver. The others are vaccines (Comirnaty) and licensing deals.
Who are Pfizer's main competitors?
Direct peers on record are GSK, Novartis, Moderna, AstraZeneca, Merck & Co. (MSD), Johnson & Johnson (Innovative Medicine), Bristol-Myers Squibb, BioNTech and Sanofi. Eli Lilly is listed as an emerging player.
Does Pfizer have an API?
No public API is recorded for Pfizer.
What industry is Pfizer in?
Pfizer's product category is Pharmaceutical Drugs and Vaccines. Its primary akta.pro industry code is HLAAAEAA, Prophylactic Human Vaccines (routine, pediatric, adult), with a secondary code of HLAAAEAC, Infectious Disease & Pandemic Preparedness Vaccines (emerging pathogens). Its NAICS code is 325414 and its SIC code is 2836.